Factors associated with long-term renal allograft survival

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 36-39

  Kaplan, Bruce ^a   Srinivas, Titte R ^a   Meier Kriesche, Herwig Ulf ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

COMORBIDITY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG MONITORING; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE;

DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036146485     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00007     Document Type: Conference Paper

References (52)

1. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant
2. Improved graft survival after renal transplantation in the United States 1988-1996
3. Survival improvement among patients with end stage renal disease: Trends over time for transplant recipients and wait-listed patients
4. Time dependency of factors affecting renal allograft survival
5. The UNOS Scientific Transplant Registry - 2000
6. Causes of death after renal transplantation
7. Chronic Allograft Dysfunction: Mechanisms and new approaches to therapy
8. Chronic humoral rejection: Identification of antibody-mediated renal allograft rejection by C4d deposits in peritubular capillaries
9. Reversibility of chronic allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury
10. Nephron underdosing: A programmed cause of chronic renal allograft failure
11. Clinical correlates to chronic renal allograft rejection
12. The Banff '97 working classification of renal allograft pathology
13. Review of transplantation
14. Addition of Rapamycin to cyclosporine-prednisone based immunosuppression reduces clinical risk of pre-transplant anti-HLA antibody
15. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival
16. The impact of HLA mismatches on first cadaver kidney graft survival
17. Experience with the Wujciak-Opelz allocation system in a single center: An increase in HLA-DR mismatching and in early rejection episodes
18. Effect of waiting time on renal transplant outcome
19. Effect of the use or non-use of dialysis on the subsequent survival of renal transplants from living donors
20. The association of waiting time with poor renal transplant outcome is unrelated to dialysis modality
21. High survival rates of kidney transplants from spousal and living donors
22. Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma dependent pathway
23. Significance of the donor age effect on kidney transplants
24. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
25. Delayed graft function: Risk factors and implications for renal allogaft survival
26. Delayed graft function in the absence of rejection has no long-term impact: A study of cadaver kidneys with good graft function at 1 year after transplantation
27. Increased incidence of acute rejection in patients with delayed graft function
28. The impact of an acute rejection episode on long-term renal allograft survival (t1/2)
29. Increased impact of acute rejection on chronic allograft failure in recent era
30. Impact of the Banff '97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation
31. The effect of acute rejection on long-term renal graft survival is mainly related to initial renal damage
32. Long term renal allograft survival: Prognostic implication of the timing of acute rejection episodes
33. Critical evaluation of the association of acute with chronic rejection in kidney and heart transplant recipients
34. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
35. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients
36. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared to Sandimmune
37. Gender differences in the risk for chronic allograft failure
38. Relationship of recipient age and development of chronic allograft failure
39. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection
40. Renal transplantation in black Americans
41. Renal function in the first year after transplantation predicts longterm survival
42. Influence of cyclosporine pharmacokinetics, trough concentration and AUC monitoring on outcome after kidney transplantation
43. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients
44. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomized comparison of two cyclosporine regimens
45. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study
46. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of acute rejection
47. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation
48. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicenter study
49. A worldwide Phase III. Randomized, controlled safety and efficacy study of a sirolimus/CsA regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
50. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
51. Improved kidney graft function in patients receiving sirolimus, cyclosporine and steroids: The role of cyclosporine blood concentration
52. Longitudinal effect of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials